Bone y-carboxyglutamic acid-containing (Gla) protein (BGP, osteocalcin) is a noncollagenous protein of bone present in plasma and removed by the kidney. Plasma BGP has been shown to be elevated in patients with certain bone diseases. The present study evaluates serum BGP (S-BGP), serum alkaline phosphatase (S-AP), and urinary hydroxyproline excretion (U-OHP) in diseases with differing bone turnover rates, and compares the accuracy of these measurements for estimating bone mineralization (m) and resorption (r) rates. S-BGP, S-AP, U-OHP, and creatinine clearance (Cl<,) were measured in patients with primary hyperparathyroidism (n = 13), hyperthyroidism (n = 6), and hypothyroidism (a = 6). Bone mineralization and resorption rates were calculated from a 7-d combined calcium balance and 47Ca turnover study. A highly significant correlation (r = 0.69, P < 0.001) was found between S-BGP and m. Multiple regression analysis disclosed a partial correlation between S-BGP and m when Cl4, was taken into account (r = 0.82, P < 0.001), and between S-BGP and Cl,. when m was taken into account (r = -0.62, P < 0.005). In accordance with this, a stronger correlation (r = 0.89, P < 0.0001) was found between S-BGP X Cl,= and m than between S-BGP and m. A less significant correlation was found between S-AP and m (r = 0.45, P < 0.05). Furthermore, U-OHP showed a highly significant positive correlation to r (r = 0.78, P < 0.001).
Introduction
Bone y-carboxyglutamic acid-containing (Gla) protein (BGP),' or osteocalcin, is a noncollagenous 49-residue protein containing variation; GFR, glomerular filtration rate; m, bone mineralization rate; r, bone resorption rate; S-AP, serum alkaline phosphatase; S-BGP, serum BGP; S-BGP X Clc, S-BGP with correction for renal function; T3, triiodothyronine; T3-test, triiodothyronine uptake test; T4, thyroxine; U-OHP, urinary excretion of hydroxyproline. two or three residues of the vitamin K-dependent amino acid y-carboxyglutamic acid (Gla) (1) (2) (3) (4) . BGP is synthesized in bone and is present in plasma (5) . Experiments in rats have shown that 3 h after injection of warfarin, an inhibitor of y-carboxylation, the BGP in serum is entirely decarboxylated, suggesting that most, if not all, BGP in serum originates from new cellular synthesis (6) , rather than from degradation of bone. The role of BGP in bone metabolism remains unknown, but serum BGP (S-BGP) is of potential interest as a specific marker of bone metabolism. Using a specific radioimmunoassay, plasma BGP levels have been shown to be elevated in patients with increased bone turnover and to correlate with plasma alkaline phosphatase in these patients (7) . In theory, it would seem that BGP may be useful for evaluating bone mineralization rate as it does not have the limitations that are inherent for serum alkaline phosphatase (S-AP) and urinary excretion of hydroxyproline (U-OHP), parameters traditionally used as indices for bone turnover. S-AP originates from bone, liver, the gastrointestinal tract, lungs, tumors, and other possible sources (8) . Moreover, the different factors affecting degradation of AP are not fully understood. U-OHP has several problems that complicate its interpretation as an index of bone resorption. It reflects dietary intake of gelatin and turnover of nonosseous as well as osseous collagen. A portion of the hydroxyproline in urine is derived from peptides related to collagen synthesis, and many ofthe hydroxyproline-containing peptides released during degradation of collagen are further metabolized and may not appear as U-OHP (9) .
In the present study we have evaluated the relationships between S-BGP, S-AP, and U-OHP, and bone mineralization (m) and resorption (r) rates at the organ level. For this purpose we have chosen groups of patients who have no mineralization defects or fractures, but in whom bone histomorphometry (10, 1 1) had previously revealed large variations in bone turnover at the tissue level. Moreover, the relative accuracy of the biochemical variables for estimating bone turnover rates was investigated with particular attention to whether the clinical significance of S-BGP measurements was improved when corrected for variations in renal function.
Methods 25 patients (20 females and 5 males) aged 26-73 yr (mean, 62 yr) with primary hyperparathyroidism (n = 13), hyperthyroidism (n = 6), and hypothyroidism (n = 6) were investigated. All serum measurements were performed on samples that were withdrawn in the morning after overnight fasting. S-BGP was measured by radioimmunoassay (5) using rabbit antisera to bovine BGP (used at 1: 35,000 dilution). The standard was bovine BGP, where the concentration was established by quantitative amino acid analysis. The tracer was prepared by chloramine-T radioiodination. The assay was 48 h nonequilibrium assay and was terminated by second antibody precipitation with goat anti-rabbit IgG. The detection limit was 0.1 ng, with a CV of 6% in the useful range (0.2-20 ng). The intraassay variation was typically <6%; the interassay variation was <10%. In our laboratory, using standardized restrictions on diet and time of serum collection as described above, the normal range for serum BGP levels is between 6 and 13 ng/ ml. Serum BGP levels > Correction for renal influence on S-BGP. Provided BGP is produced in an amount proportional to m, then, production rate of BGP (p-BGP) = k,, a constant. Assuming that the degradation of BGP (d-BGP) is determined by the renal function and serum level of BGP, then d-BGP = k2 X Clv. X S-BGP, where Clt, is the creatinine clearance rate; and S-BGP, the serum concentration of BGP. Because of the low molecular weight ofBGP (5, 800) , it is reasonable to assume that BGP is completely diffusible. Consequently, the expression S-BGP X Clv. is equivalent to the filtered load of BGP.
In 
Results
A close relation (r = 0.89, P < 0.0001) was observed between r and m (Fig. 1 ). It appears that with increasing bone turnover, r increases more than m, leading to a progressive negative calcium balance. This was confirmed by a negative correlation (r = -0.64, P < 0.005) between m and calcium balance. This coupling between r and m to some extent compromises the utility of linear regression analysis to determine the dependence of biochemical markers on bone resorption and bone formation. A significant correlation (r = 0.69, P < 0.001) was found between S-BGP and m (Table I) (Table II) . Linear regression analysis demonstrated a significant positive correlation between S-AP and m (r = 0.45, P < 0.05) (Table I) , whereas no significant correlation was found between S-AP and S-BGP (r = 0.30, P > 0.10) or S-BGP X Cl,. (r = 0.33, P > 0.10).
Moreover, highly significant positive correlations were found between U-OHP and both r (r = 0.77, P < 0.001) and m (r = 0.74, P < 0.001) ( Table I) . Multiple regression analysis (Table  II) showed no significant partial correlations between these parameters, although the partial correlation between U-OHP and r almost reached the commonly accepted significance level. A significant positive correlation was found between U-OHP and S-BGP (r = 0.44, P < 0.05), and between U-OHP and S-BGP X Clcr (r = 0.68, P < 0.001).
In accordance with the observation above, that S-BGP depended on both m and Clcr, a stronger correlation was found between S-BGP X Clv, and m than between S-BGP and m (Fig.   2 ). In the patients studied m could be predicted from the corrected S-BGP with an average error of 3.2 mmol Ca/d, whereas the error of the estimate was 5.2 mmol Ca/d using the uncorrected S-BGP, and 6.7 mmol Ca/d using S-AP (Table I) ; r could be estimated with an error of 4.7 mmol Ca/d using U-OHP. Table III contains the results of linear regression analysis performed to evaluate whether identical relations exist between m and S-BGP, and between m and S-BGP X Clv. in patients with thyroid and parathyroid disorders. For both types of metabolic disturbances, the level of significance and the standard error ofestimate improved after correction of S-BGP for changes in renal function. Furthermore, following this correction, no significant differences were found between the two types of disorders in either the slope or the intercept of the regression lines.
Discussion
Our data demonstrate that S-BGP levels depend on m and renal function in the 25 patients with parathyroid and thyroid disorders (17, 18 ).
In the study described here we deliberately chose patients with a wide spectrum of bone turnover rates, but who were not suspected to have mineralization defects, since estimation of m by calcium kinetics may be compromised in patients with osteomalacia or rickets (19) . The increased amount of osteoid observed in some hyperparathyroid and hyperthyroid patients (10) is not caused by a mineralization defect with increased osteoid seam width, as is seen in osteomalacia, but rather is secondary to the enhanced activation of new remodeling cycles leading to increased osteoid surface. Furthermore, in the estimation of m, the applied expanding exchangeable calcium pool model compensates for variation in the amount of long term exchangeable calcium (14, 20) .
We found no significant partial correlation between S-BGP and r when the influence ofrenal function and m was taken into account. These findings are corroborated by a histomorphometric study on 26 postmenopausal women with osteoporosis (21) which showed a positive correlation between S-BGP and tetracycline-based indices of bone formation at tissue level, but not to resorption surfaces. Furthermore, in vitro studies on rat osteogenic sarcoma cells (22) and studies on warfarin-treated rats (6) support the concept that BGP is produced by osteoblasts during de novo synthesis of matrix proteins.
S-BGP corrected for the influence of variations in renal function (S-BGP X Cl,) was found to be more accurate than the uncorrected S-BGP in predicting the m. Furthermore, no significant differences were found between the slopes or intercepts of the regression lines describing the relations between the corrected S-BGP and m in either thyroid or parathyroid disorders. Hence, in the investigated patients, the observed relationship appears to be independent ofthe pathophysiological mechanisms for the altered bone turnover.
The highly significant correlation found between m and r in the present study is consistent with the well-known coupling between resorption and formation at tissue level (23) . This coupling insures the integrity ofbone mass in spite of large variations in bone remodeling rates. However, a negative correlation between bone balance and m was observed. This may be partly explained by an expansion of the remodeling space in a nonsteady state situation with increasing bone turnover due to the sequential separation between bone resorption and formation, where the former always precedes the latter. Also contributing may be an acceleration of an age-related or -induced negative net balance per remodeling cycle. This close coupling between bone resorption and mineralization might explain why S-BGP, S-BGP X Cl, and U-OHP all showed significant correlations to both m and r, and a positive correlation between S-BGP, S-BGP X Cl, and U-OHP using linear least squares regression analysis. However, no significant partial correlation was found between r and S-BGP when multiple regression analysis was used to correct for the influence of m and renal function. By linear regression analysis, S-BGP corrected for renal function showed a higher correlation with m than did S-BGP alone. In addition, the correlation between S-BGP and m was improved by conditioning CL,. in the multiple regression analysis.
In the present study we found S-BGP was superior to S-AP in predicting m, especially after S-BGP is corrected for variations in renal function. We did, however, find a significant positive correlation between S-AP and m, consistent with the observations of Klein et al. (24) .
The apparently better predictive value ofS-BGP may be due to the fact that alkaline phosphatase is derived from a number of different tissues with several production and degradation rates (8) . In the thyroid disorders, for instance, the degradation of alkaline phosphatase may be enhanced in hyperthyroidism and reduced in hypothyroidism, resulting in a smaller variation in S-AP than expected from the variations in bone turnover.
This study has demonstrated that serum levels of BGP in the studied calcium metabolic disorders depend on both the m and the renal function. Moreover, in the investigated patients, S-BGP corrected for alterations in renal function were superior to uncorrected values and to S-AP in the estimation of m.
